Adverse cardiovascular and kidney outcomes in people with SARS-CoV-2 treated with SGLT2 inhibitors.

Taeyoung ChoiYan XieZiyad Al-Aly

Published in: Communications medicine (2024)

Among people with SARS-CoV-2 infection on antihyperglycemic therapy, compared to those on other antihyperglycemics, those on SGLT2 inhibitors have less risk of adverse cardiovascular and kidney outcomes.

Keyphrases

sars cov
respiratory syndrome coronavirus
emergency department
type diabetes
adipose tissue
coronavirus disease
insulin resistance
newly diagnosed